MARIETTA, Ga., Nov. 14, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short sellers.
Parker H. "Pete" Petit, Chairman and CEO, stated, "MiMedx will continue to expose the false allegations and contrived innuendo propagated by these illegal short-sellers, especially those that are associated with the Company's compliance with regulatory requirements. Their baseless allegations are simply designed to denigrate the Company's reputation in order to reinforce the short-sellers' theme of 'short and distort.' The business practices and supportive culture of the Company have been well-established for many years, and they are based on honesty and integrity. The sources used by these short-sellers and their 'Free Speech' shills appear to include a few former employees who were terminated for cause. Many of their allegations have already been discredited through the discovery process, and they will be further discredited as these matters come to trial. Most of the negative innuendo in this category is quite ridiculous, and it is hard to believe it could be taken as credible."
The new materials can be found on the MiMedx website, www.mimedx.com, by clicking on the tab "Short Selling Commentary" found on the homepage.
MiMedx® is the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. "Innovations in Regenerative Medicine" is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.
Important Cautionary Statement
This press release includes forward-looking statements, including statements regarding false allegations the Company believes are propagated by short sellers to manipulate the price of the Company's stock as part of a "short and distort" campaign, the Company's belief that former employees who were terminated for cause are providing meritless information to the shortsellers, the Company's belief that the allegations of the former employees will be further discredited through discovery, and the Company's belief that many of the statements made by reporting shills for short sellers are misleading to investors. These statements also may be identified by words such as "believe," "except," "may," "plan," "potential," "will" and similar expressions, and are based on our current beliefs and expectations. Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that different or additional facts may be discovered that change conclusions, and the risks of litigation. For more detailed information on the risks and uncertainties, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.
SOURCE MiMedx Group, Inc.